These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 26698156)
1. Increased lanosterol turnover: a metabolic burden for daunorubicin-resistant leukemia cells. Stäubert C; Krakowsky R; Bhuiyan H; Witek B; Lindahl A; Broom O; Nordström A Med Oncol; 2016 Jan; 33(1):6. PubMed ID: 26698156 [TBL] [Abstract][Full Text] [Related]
2. Anticancer effects of Annona glabra plant extracts in human leukemia cell lines. Cochrane CB; Nair PK; Melnick SJ; Resek AP; Ramachandran C Anticancer Res; 2008; 28(2A):965-71. PubMed ID: 18507043 [TBL] [Abstract][Full Text] [Related]
3. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines. Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632 [TBL] [Abstract][Full Text] [Related]
4. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia. Verrills NM; Po'uha ST; Liu ML; Liaw TY; Larsen MR; Ivery MT; Marshall GM; Gunning PW; Kavallaris M J Natl Cancer Inst; 2006 Oct; 98(19):1363-74. PubMed ID: 17018783 [TBL] [Abstract][Full Text] [Related]
5. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine. Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070 [TBL] [Abstract][Full Text] [Related]
6. Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein. Haber M; Norris MD; Kavallaris M; Bell DR; Davey RA; White L; Stewart BW Cancer Res; 1989 Oct; 49(19):5281-7. PubMed ID: 2569932 [TBL] [Abstract][Full Text] [Related]
7. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells. Morgan SE; Kim R; Wang PC; Bhat UG; Kusumoto H; Lu T; Beck WT Oncogene; 2000 Oct; 19(43):5010-9. PubMed ID: 11042688 [TBL] [Abstract][Full Text] [Related]
8. Reversal of P-glycoprotein-mediated multidrug resistance by cholesterol derived from low density lipoprotein in a vinblastine-resistant human lymphoblastic leukemia cell line. Shu Y; Liu H Biochem Cell Biol; 2007 Oct; 85(5):638-46. PubMed ID: 17901905 [TBL] [Abstract][Full Text] [Related]
9. Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts. Beck WT; Cirtain MC; Lefko JL Mol Pharmacol; 1983 Nov; 24(3):485-92. PubMed ID: 6579344 [TBL] [Abstract][Full Text] [Related]
10. Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent. Chen YY; Lukka PB; Joseph WR; Finlay GJ; Paxton JW; McKeage MJ; Baguley BC Cancer Chemother Pharmacol; 2014 Jul; 74(1):25-35. PubMed ID: 24801172 [TBL] [Abstract][Full Text] [Related]
12. Reverse-phase protein microarrays (RPPA) as a diagnostic and therapeutic guide in multidrug resistant leukemia. Maraldi T; Bertacchini J; Benincasa M; Guida M; De Pol A; Liotta LA; Petricoin E; Cocco L; Marmiroli S Int J Oncol; 2011 Feb; 38(2):427-35. PubMed ID: 21132263 [TBL] [Abstract][Full Text] [Related]
13. Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance. Yamauchi T; Ogawa M; Ueda T Mol Pharmacol; 2008 Jul; 74(1):82-91. PubMed ID: 18430789 [TBL] [Abstract][Full Text] [Related]
14. Sterol biosynthesis by a prokaryote: first in vitro identification of the genes encoding squalene epoxidase and lanosterol synthase from Methylococcus capsulatus. Nakano C; Motegi A; Sato T; Onodera M; Hoshino T Biosci Biotechnol Biochem; 2007 Oct; 71(10):2543-50. PubMed ID: 17928701 [TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity of artesunic acid homo- and heterodimer molecules toward sensitive and multidrug-resistant CCRF-CEM leukemia cells. Horwedel C; Tsogoeva SB; Wei S; Efferth T J Med Chem; 2010 Jul; 53(13):4842-8. PubMed ID: 20527917 [TBL] [Abstract][Full Text] [Related]
16. Glucocorticoid-receptor-gene defects and resistance to glucocorticoid-induced apoptosis in human leukemic cell lines. Hala M; Hartmann BL; Böck G; Geley S; Kofler R Int J Cancer; 1996 Nov; 68(5):663-8. PubMed ID: 8938150 [TBL] [Abstract][Full Text] [Related]
17. Selective and brain-penetrant lanosterol synthase inhibitors target glioma stem-like cells by inducing 24(S),25-epoxycholesterol production. Nguyen TP; Wang W; Sternisha AC; Corley CD; Wang HL; Wang X; Ortiz F; Lim SK; Abdullah KG; Parada LF; Williams NS; McBrayer SK; McDonald JG; De Brabander JK; Nijhawan D Cell Chem Biol; 2023 Feb; 30(2):214-229.e18. PubMed ID: 36758549 [TBL] [Abstract][Full Text] [Related]
18. Cytotoxic effects of folate antagonists against methotrexate-resistant human leukemic lymphoblast CCRF-CEM cell lines. Mini E; Moroson BA; Franco CT; Bertino JR Cancer Res; 1985 Jan; 45(1):325-30. PubMed ID: 3855284 [TBL] [Abstract][Full Text] [Related]
19. Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells. Gayet L; Dayan G; Barakat S; Labialle S; Michaud M; Cogne S; Mazane A; Coleman AW; Rigal D; Baggetto LG Biochemistry; 2005 Mar; 44(11):4499-509. PubMed ID: 15766280 [TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis of histone H3 and H4 post-translational modifications in doxorubicin-resistant leukemia cells. Liu T; Guo Q; Guo H; Hou S; Li J; Wang H Biomed Chromatogr; 2016 Apr; 30(4):638-44. PubMed ID: 26317407 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]